Increasing Instances of Chromosomal Abnormalities to drive the demand for Non-invasive Prenatal Testing

The Tidbits

Non-invasive Prenatal Testing (NIPT) comes into picture anytime post 9 weeks of pregnancy. In other words, it is performed before prenatal screening/diagnostic test. NIPT was initially recommended for only those women who were into the high-risk pregnancy zone (aged 35 and above). However, in the current scenario, Non Invasive Prenatal Testing is recommended for all the pregnant women, regardless of their ages, as chromosomal abnormalities are found in these women’s foetuses as well.

Besides, CDC states that median age of the first-time pregnancies in the US has been 26.3 since 2014 (was 24.9 before that). In EU, this age is 29.1 as per Eurostat. In Australia, it’s 29 years since the year 2016 (was 27.8 years before that). At the same time, it needs to be noted that patients who weigh more than 250 pounds may get inappropriate results as stated by Non—invasive Prenatal Testiing Services to Change for Texas Medicaid.

Along the above-mentioned lines, Natera, in December 2020, did announce an expanded coverage from Aetna, the biggest US Health Plan regarding non-invasive prenatal testing to every pregnancy. This was an outcome of guidelines pertaining to aneuploidy screening options that were published by the ACOG (American College of Obstetricians and Gynaecologists) in partnership with SMFM (Society for Maternal-Fetal Medicine).

Additionally, after Progenity Inc. launching Resura prenatal test for monogenic disease by making use for sequencing-based non-invasive cell-free DNA technology, the NIPT market is on its way to making greater strides. Also, numerous academic and commercial laboratories like NIPD Genetics in Cyprus, the Chinese University of Hong Kong Berry Genomics, BGI Health, Germany-based LifeCodexx, and Radboud University based in the Netherlands are into expansion of their businesses in cfDNA-based NIPT market for various genetic conditions (including aneuploidies).

Persistence market Research has captured every detail on this front in its latest market study entitled “Non-Invasive Prenatal Testing market”.

Non-invasive Prenatal Testing Market: The way it’s categorized

The global non-invasive prenatal testing market, by gestation period, includes 0-12 weeks, 25-36 weeks and 13-24 weeks. By risk type, it’s low and high & average. By method, it’s ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. Technology-wise, it’s array technology, NGS, PCR, and others. By product, it’s instruments and consumables & reagents. By end-use, it’s diagnostic laboratories and hospitals & clinics. By application, it's trisomy, microdeletion syndrome, and others (Rhesus (Rh) blood type, Klinefelter syndrome, and detecting monogenetic disorders).

Out of these, cell-free DNA in maternal plasma tests holds the largest market share due to advancements in technology. Application-wise, trisomy is the highest revenue generator. End-user-wise, diagnostic laboratories are on the driver’s seat. Persistence Market Research has systematically stated these facts through statistics along with insights regarding the same.

Region-wise Analysis

North America holds more than 40% of the market share in terms of revenue. This could be credited to NIPT being adopted at a wider scale all across the US. However, it does lack regarding national consensus policies herein. Europe stands second on the similar grounds. However, the Asia-Pacific is expected to grow at the fastest rate in the non-invasive prenatal testing market with companies like China-based BGI leading from the front. India won’t be behind either, as stated by Persistence Market Research in its study mentioned above.

It has also mentioned that LATAM will be a significant placeholder in the NIPT market in the upcoming period. This is evident from countries like Mexico and Brazil opening an arena in this regard.

The Competitors mean the following….

Persistence Market Research has profiled the key market participants as follows:

• Illumina, Inc.
• GE Healthcare
• BGI
• Thermo Fisher Scientific, Inc.
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Yourgene Health

It has also moved further with sketching the major developments. For instance – BGI, along with Eluthia, tabled the NIFTY test under the brand name “PreviaTest” all across Germany. This happened in June 2019. Plus, Illumina, in January 2019, did carry out the expansion of its NIPT platform by launching VeriSeq NIPT Solution v2. The same Illumina, in November 2018, inked an agreement with Pacific Biosciences for acquiring the latter. This, thus, let the former impart strength to its sequencing solutions with precise long-read sequencing capabilities.

Overall, non-invasive prenatal testing market is there to stand taller amongst the other arms of gynecology in the next decade with indispensability revolving around it – Persistence Market Research.